News
May 22 2024
Could a person with Type 1 diabetes re-grow their own pancreas? A San Antonio study is about to find out
Dr. Sherwyn Schwartz is interviewed on KSAT-TV regarding Endeavor Clinical Trials’ entry into research for Type 1 Diabetes treatment. To read the full article CLICK HERE!
June 3, 2019
Endeavor Clinical Trials participates in Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
Endeavor Clinical Trials was one of the sites that participated in the second pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 24 hours (SPID24) compared to placebo in patients with postoperative pain following abdominoplasty surgery. In addition, the trial met all of its key secondary endpoints. The study also includes a standard-of-care IV opioid as an active comparator: IV morphine 4 mg. In this study, IV tramadol also demonstrated similar efficacy and safety to that of IV morphine.
CLICK HERE to read about the positive topline results from the phase 3 clinical trial
October 3, 2018
Endeavor interview on KEDA Radio
Dr. Sherwyn Schwartz, Lisa Rodriguez, and Henry Rodriguez pose for a picture after their time on-the-air at KEDA radio.
Dr. Sherwyn Schwartz, Lisa Rodriguez, and Henry Rodriguez discuss new initiative to reach San Antonio Hispanic community with Type II Diabetes.
September 18, 2018
TECH SA: New device measures temperatures for diabetics at risk of foot ulcers
Device is connected to app for convenience, makers say
Endeavor Clinical Trials the sole site selected to study the device prior to going to market.
CLICK HERE to read about the device and how it helps diabetics at risk of foot ulcers.
March 20, 2018
Endeavor Clinical Trials participates in bringing new non-opioid pain control medicine to the market
Endeavor Clinical Trials was one of the sites that participated in studies investigating a non-opioid postoperative pain medicine. The sponsor, Heron Therapeutics, has announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2). HTX-011 achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically significant reductions in both pain intensity and the use of opioid rescue medications through 72 hours following surgery.
CLICK HERE to read about the positive topline results from the phase 3 clinical trials.
